



Express Mail N .: EV 335 855 710 US

#7
7/12/03
RECEIVED
JUL 02 2003
FBI CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Sakata et al.

Confirmation No.: 8859

Application No.: 10/071,390

Group Art Unit: 1626

Filed: February 7, 2002

Examiner: R. Gerstl

For: ISOTHIAZOLOANTHRONRES,
ISOXAZOLOANTHRONES,
ISOINDOLANTHRONES AND
DERIVATIVES THEREOF AS
JNK INHIBITORS AND
COMPOSITIONS AND
METHODS RELATED THERETO

Attorney Docket No.: 10624-053-999

**RESPONSE TO RESTRICTION REQUIREMENT
WITH TRAVERSE UNDER 37 C.F.R. §1.143**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This responds to the Office Action mailed March 25, 2003. Applicants concurrently submit herewith: (a) a Petition for Extension of Time for two (2) months Under 37 C.F.R. 1.136(a) with provision for fee (in duplicate); and (b) a Second Supplemental Information Disclosure Statement, including a Form PTO-1449 listing references CP-CS (a copy of references CP-CS being enclosed).

REMARKS

A Restriction Requirement under 35 U.S.C. §121 has been entered in the present application. The Restriction Requirement identifies three groups:

- Group I. Claims 1-14, 109 and 110, drawn to compounds;
- Group II. Claims 15-29, drawn to compositions; and
- Group III. Claims 30-108, drawn to methods.